BG
AMRI

BlackRock Group’s Albany Molecular Research Inc AMRI Stock Holding History

BlackRock Group’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$816K Buy
43,519
+12,055
+38% +$205K ﹤0.01% 2210
2016
Q3 		$520K Buy
31,464
+1,778
+6% +$26.3K ﹤0.01% 2304
2016
Q2 		$399K Buy
29,686
+4,541
+18% +$66.2K ﹤0.01% 2343
2016
Q1 		$385K Buy
25,145
+2,921
+13% +$45.8K ﹤0.01% 2342
2015
Q4 		$442K Buy
22,224
+964
+5% +$18.3K ﹤0.01% 2248
2015
Q3 		$370K Buy
21,260
+2,228
+12% +$45.4K ﹤0.01% 2319
2015
Q2 		$385K Buy
19,032
+7,541
+66% +$146K ﹤0.01% 2358
2015
Q1 		$202K Buy
11,491
+205
+2% +$3.49K ﹤0.01% 2495
2014
Q4 		$184K Sell
11,286
-1,088
-9% -$20K ﹤0.01% 2542
2014
Q3 		$273K Buy
12,374
+2,254
+22% +$46.2K ﹤0.01% 2367
2014
Q2 		$204K Buy
+10,120
New +$171K ﹤0.01% 2454
2013
Q4 		– Sell
-10,991
Closed -$142K – 2860
2013
Q3 		$142K Buy
+10,991
New +$135K ﹤0.01% 2552

Other funds holding AMRI

PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

BlackRock Group's AMRI Position: Q4 2016 in Review

BlackRock Group increased its Albany Molecular Research Inc (AMRI) stake by 38% in Q4 2016, buying an estimated $205K and bringing the position to 43,519 shares worth $816K. The position accounts for ﹤0.01% of the portfolio, ranked #2210.

BlackRock Group first reported a position in AMRI in Q3 2013 and has held it in 12 quarters since. 133 funds tracked by Wall St. Rank hold AMRI as of Q4 2016.

  • BlackRock Group held 43,519 shares of Albany Molecular Research Inc worth $816K as of Q4 2016.
  • BlackRock Group bought 12,055 Albany Molecular Research Inc shares in Q4 2016, an estimated $205K.
  • Albany Molecular Research Inc made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2210 holding.
  • BlackRock Group first reported a position in Albany Molecular Research Inc in Q3 2013 and has held it in 12 quarters since.
  • 133 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.